SCHEMBL4726259

SCHEMBL4726259

CC(C)(NCc1cc(Br)ccn1)C(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.39
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RAB9A P51151 3/20 0.35
NPC1 O15118 2/20 0.35
PLAU P00749 2/20 0.35
PLG P00747 1/20 0.35
PLAT P00750 1/20 0.35
KDM5A P29375 1/20 0.34
KDM5C P41229 1/20 0.34
KDM5D Q9BY66 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
AR P10275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4726263 0.78 KDM4E (0.40) CYP1A2KDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL4906644 0.76 PSEN1 (0.43) CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6
Hydrochloric Acid SCHEMBL4899189 0.75 PSEN1 (0.43) CYP1A2CYP3A4CYP2C9CYP2C19CYP2D6
SCHEMBL15543495 0.74 NPSR1 (0.50) CYP1A2KDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL30001281 0.74 NPSR1 (0.50) CYP1A2KDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL4904071 0.74 CYP1A2 (0.51) CYP1A2KDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL17309330 0.73 KDM4A (0.43)
SCHEMBL14258733 0.73 SCN9A (0.43) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL29186948 0.72 S1PR1 (0.36) CYP1A2KDM4ECYP3A4CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL4904250 0.72 SCN9A (0.42) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058391-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-03-06 US disclosed
US-20080058391-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-03-06 US disclosed
US-20080058391-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-03-06 US disclosed
WO-2008017691-A1 PYRIDINE DERIVATIVES AS SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2008-02-14 WO disclosed
WO-2008017691-A1 PYRIDINE DERIVATIVES AS SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2008-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058391-A1 NOVEL COMPOUNDS HCN3, KCNN3, HCN4 CYP1A2 1926/4885KDM4E 2966/4885CYP3A4 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.